AR039986A1 - Metodo para reducir el dolor usando virus oncoliticos - Google Patents

Metodo para reducir el dolor usando virus oncoliticos

Info

Publication number
AR039986A1
AR039986A1 ARP030101621A ARP030101621A AR039986A1 AR 039986 A1 AR039986 A1 AR 039986A1 AR P030101621 A ARP030101621 A AR P030101621A AR P030101621 A ARP030101621 A AR P030101621A AR 039986 A1 AR039986 A1 AR 039986A1
Authority
AR
Argentina
Prior art keywords
mammal
viruses
reducing pain
oncolitical
analgesic
Prior art date
Application number
ARP030101621A
Other languages
English (en)
Spanish (es)
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of AR039986A1 publication Critical patent/AR039986A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • A61K35/765Reovirus; Rotavirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12211Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP030101621A 2002-05-09 2003-05-08 Metodo para reducir el dolor usando virus oncoliticos AR039986A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37867502P 2002-05-09 2002-05-09
US44317703P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
AR039986A1 true AR039986A1 (es) 2005-03-09

Family

ID=29423642

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030101621A AR039986A1 (es) 2002-05-09 2003-05-08 Metodo para reducir el dolor usando virus oncoliticos

Country Status (19)

Country Link
US (2) US20040091458A1 (enExample)
EP (1) EP1505992B1 (enExample)
JP (1) JP5241059B2 (enExample)
AR (1) AR039986A1 (enExample)
AT (1) ATE404213T1 (enExample)
AU (1) AU2003229431B8 (enExample)
BR (1) BR0309825A (enExample)
CA (1) CA2484398C (enExample)
DE (2) DE03722131T1 (enExample)
DK (1) DK1505992T3 (enExample)
ES (1) ES2239928T3 (enExample)
IL (1) IL164695A (enExample)
MX (1) MXPA04011007A (enExample)
NZ (1) NZ536102A (enExample)
PT (1) PT1505992E (enExample)
SI (1) SI1505992T1 (enExample)
TR (1) TR200501460T3 (enExample)
TW (1) TWI316405B (enExample)
WO (1) WO2003094938A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
MX339014B (es) * 2008-05-27 2016-05-09 Oncolytics Biotech Inc Modulacion de presion intersticial y suministro y distribucion viral oncolitica.
KR20100054358A (ko) * 2008-11-14 2010-05-25 김재은 스틱 연고
AU2010242748B2 (en) * 2009-05-01 2015-07-23 Adare Pharmaceuticals, Inc. Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
EP2383577A1 (en) * 2010-04-30 2011-11-02 Deutsches Krebsforschungszentrum Diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy
CA2990133A1 (en) 2015-06-19 2017-03-09 Sillajen, Inc. Compositions and methods for viral embolization
AU2017221592A1 (en) 2016-02-16 2018-10-04 Osaka University Pharmaceutical composition for use in treating fibrosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6110461A (en) * 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
NZ518945A (en) * 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus

Also Published As

Publication number Publication date
EP1505992A1 (en) 2005-02-16
NZ536102A (en) 2008-01-31
BR0309825A (pt) 2005-03-01
CA2484398C (en) 2014-01-21
DE03722131T1 (de) 2005-09-15
ATE404213T1 (de) 2008-08-15
AU2003229431B8 (en) 2009-07-02
AU2003229431A1 (en) 2003-11-11
US20040091458A1 (en) 2004-05-13
EP1505992B1 (en) 2008-08-13
JP2005526124A (ja) 2005-09-02
PT1505992E (pt) 2008-10-06
WO2003094938A1 (en) 2003-11-20
DE60322885D1 (de) 2008-09-25
ES2239928T1 (es) 2005-10-16
IL164695A0 (en) 2005-12-18
IL164695A (en) 2010-12-30
SI1505992T1 (sl) 2009-02-28
HK1070565A1 (en) 2005-06-24
TW200402305A (en) 2004-02-16
JP5241059B2 (ja) 2013-07-17
CA2484398A1 (en) 2003-11-20
AU2003229431B2 (en) 2008-01-17
TWI316405B (en) 2009-11-01
DK1505992T3 (da) 2008-10-06
TR200501460T3 (tr) 2005-06-21
US20080081032A1 (en) 2008-04-03
ES2239928T3 (es) 2009-02-16
MXPA04011007A (es) 2005-02-14

Similar Documents

Publication Publication Date Title
AR039986A1 (es) Metodo para reducir el dolor usando virus oncoliticos
ES2528384T3 (es) Métodos de utilización de inhibidores del receptor de adenosina para potenciar la respuesta inmunitaria y la inflamación
NO985821L (no) Substituerte syklopentanforbindelser som er nyttige som neuraminidaseinhibitorer
AR032912A1 (es) Formulacion farmaceutica
AR034746A1 (es) Combinaciones para el tratamiento de trastornos inflamatorios
CO5680108A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
EA200500859A1 (ru) Хинолинилпирролопиразолы
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
DK1071417T3 (da) Anvendelse af cannabidiol som anti-inflammatorisk middel
UY28287A1 (es) Combinaciones para el tratamiento de enfermedades que impican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
BRPI0516531A (pt) imunoterapia de distúrbios auto-imunes
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
ATE348630T1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
NO20051170L (no) Terapeutiske kombinasjoner av erb-B-kinase inhibitorer og anti-neoplastiske terapier
NO20051654L (no) Forlenget frigjoring av farmasoytisk preparat
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
EA200100540A1 (ru) Фармацевтическая композиция с модифицированным высвобождением сенсибилизатора к инсулину
AR047726A1 (es) Metodos y reactivos para el tratamiento de trastornos inflamatorios
WO2019204332A3 (en) Pak4 inhibitors and methods of use
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
CU22999A1 (es) Método de tratamiento de enfermedades malignas e infecciosas crónicas
EA200500774A1 (ru) Новая синергетическая комбинация, включающая рофлумиласт и формотерол

Legal Events

Date Code Title Description
FB Suspension of granting procedure